<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30241" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Tolterodine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Narain</surname>
            <given-names>Shreya</given-names>
          </name>
          <aff>Nova Southeastern University College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shreya Narain declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30241.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Tolterodine is a medication used in the management and treatment of overactive bladder. It is in the antimuscarinic class of medications. This activity outlines the indications, action, and contraindications for tolterodine as a valuable agent in treating overactive bladder. This activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interactions) pertinent for members of the healthcare team in the treatment of patients with overactive bladder and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of tolterodine.</p></list-item><list-item><p>Describe the potential adverse effects of tolterodine.</p></list-item><list-item><p>Review the appropriate monitoring necessary when using tolterodine.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance tolterodine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30241&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30241">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30241.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Tolterodine is a tertiary amine and serves as an antimuscarinic medication indicated in patients with an overactive bladder (OAB), including increased urgency and frequency to urinate.<xref ref-type="bibr" rid="article-30241.r1">[1]</xref>&#x000a0;This drug serves as a gold standard treatment for OAB, is regarded as the third most favorable antimuscarinic, and has a decreased level of adverse effects compared to other alternatives, such as oxybutynin.<xref ref-type="bibr" rid="article-30241.r2">[2]</xref><xref ref-type="bibr" rid="article-30241.r3">[3]</xref>&#x000a0;Patient tolerance of tolterodine&#x000a0;is significantly better than oxybutynin regarding the incidence and severity of dry mouth. Also, fewer dropouts of patients occur with tolterodine as compared to oxybutynin. Clinical studies have shown that combination therapy of tolterodine with an alpha-blocker, such as tamsulosin, significantly improves symptoms.<xref ref-type="bibr" rid="article-30241.r4">[4]</xref> Compared to placebo, tolterodine 4 mg did not prove to be effective in reducing nocturia episodes.<xref ref-type="bibr" rid="article-30241.r5">[5]</xref>&#x000a0;In comparison to tolterodine, a&#x000a0;&#x003b2;-adrenoceptor agonist called mirabegron is better tolerated by patients. It has a higher patient preference and shows better improvements in symptoms of OAB. Although both treatments are well tolerated, the anticholinergic side effects of tolterodine were higher than those of mirabegron.<xref ref-type="bibr" rid="article-30241.r1">[1]</xref></p>
      </sec>
      <sec id="article-30241.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Tolterodine is an antimuscarinic medication that selectively and competitively binds to muscarinic M3 receptors in the bladder, thereby decreasing bladder contraction by decreasing detrusor muscle tone and increasing internal urethral sphincter tone. Upon administration, it undergoes first-pass metabolism, where CYP2D6 metabolizes the drug to its active form, 5-hydroxymethyl.<xref ref-type="bibr" rid="article-30241.r6">[6]</xref></p>
      </sec>
      <sec id="article-30241.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Tolterodine administration occurs in two different ways &#x02013; orally or transdermally as a topical gel formulation (proniosomes).</p>
        <p>
<bold>Oral</bold>
</p>
        <p>Orally, it is available in two forms: immediate-release (IR) and extended-release (ER) (i.e., administering tolterodine ER 4mg once daily is pharmacokinetically equivalent to tolterodine ER 2mg twice daily).&#x000a0;</p>
        <p>
<bold>Adults </bold>
</p>
        <p>The initial dosage for IM begins at 2mg, twice daily, and has been shown to decrease the number of micturition every 24 hours, whereas EM is given as 4mg once a day.<xref ref-type="bibr" rid="article-30241.r7">[7]</xref> The IM and ER dose can be decreased to 1mg twice a day and 2mg once a day, respectively, depending on the individual reaction to the drug and tolerability. &#x000a0;</p>
        <p>A clinical study regarding male overactive bladder symptoms shows an increased effect of tolterodine ER compared to tolterodine IM.<xref ref-type="bibr" rid="article-30241.r3">[3]</xref>&#x000a0;Tolterodine EM also manifests fewer adverse effects.<xref ref-type="bibr" rid="article-30241.r2">[2]</xref></p>
        <p>
<bold>Pediatric </bold>
</p>
        <p>Doses from 0.03 to 0.12mg/kg are considered safe for children from the ages of 1 month to 15 years. A clinical study showed that the drug was well-tolerated, and there was no relationship between the dose levels and adverse events; however, complete safety and efficacy have not been established.<xref ref-type="bibr" rid="article-30241.r8">[8]</xref></p>
        <p>
<bold>Transdermal Topical Gel Formation (proniosomes)</bold>
</p>
        <p>A study on transdermal patches&#x000a0;demonstrated similar therapeutic effects&#x000a0;as the oral&#x000a0;dose form, but it&#x000a0;showed a decrease in the&#x000a0;adverse effects of the drug, such as dry mouth and constipation. Both transdermal and oral administration of tolterodine had a similar level of inhibitory effects in the bladder.<xref ref-type="bibr" rid="article-30241.r9">[9]</xref>&#x000a0;Additionally, this method of administration was effective for over 72 hours after the application because of the constant entry into the systemic circulation through the patch.</p>
      </sec>
      <sec id="article-30241.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of tolterodine are significantly lower than that of other antimuscarinic drugs indicated for the same use. &#x000a0;</p>
        <p>However, the following effects are still present:</p>
        <list list-type="bullet">
          <list-item>
            <p>Dry mouth</p>
          </list-item>
          <list-item>
            <p>Dry eyes</p>
          </list-item>
          <list-item>
            <p>Constipation</p>
          </list-item>
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Blurred vision</p>
          </list-item>
          <list-item>
            <p>Drowsiness</p>
          </list-item>
        </list>
        <p>Elderly patients who use multiple medications are more at risk for adverse effects because of drug-to-drug interactions.</p>
        <p>Considering more clinically relevant adverse effects, tolterodine has the potential to cause disturbances in the cardiac and central nervous systems. Because of muscarinic receptors in the heart, low doses of tolterodine can cause an increase in heart rate by acting on M1 and leading to tachycardia, palpitations, and cardiac rhythm disorders. Due to this potential adverse effect, the suggestion is that those with any heart-related problems use caution when taking this drug. In the central nervous system, all five subtypes of the muscarinic receptors are present, and because of the lipophilicity of tolterodine, it can cross the blood-brain barrier. This situation can give rise to CNS problems such as depression, cognitive impairment, confusion, or the most common effect, dizziness. Therefore, any patients with pre-existing neurological conditions should be cautious, and further advisement from their physician is strongly recommended.&#x000a0;</p>
      </sec>
      <sec id="article-30241.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Along with other OAB drugs, tolterodine is contraindicated in patients at risk for or currently have gastric retention or uncontrolled angle-closure glaucoma. It is also not for use in patients with myasthenia gravis, severe constipation, intestinal atony, ulcerative colitis, or bladder outflow obstructions.<xref ref-type="bibr" rid="article-30241.r10">[10]</xref></p>
        <p>Because of its tertiary property, tolterodine should be monitored and used with caution if the patient has a neurological disorder or neurodegenerative disease. Additionally, if a patient is about to perform a potentially dangerous task, this medication should not be administered, as it can cause drowsiness and blurred vision.</p>
      </sec>
      <sec id="article-30241.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Healthcare professionals should monitor patients for antimuscarinic effects on the cardiac and central nervous systems. These effects include tachycardia, palpitations, prolonged QT intervals (more common in females), hallucinations, confusion, dizziness, and more. This vigilance is vital for elderly patients taking multiple medications and who are at risk for drug-to-drug interactions.</p>
        <p>Patients should be explained the most common adverse side effects, such as dizziness, after administration of tolterodine, as it can put them at risk if they are about to perform a potentially dangerous task.</p>
      </sec>
      <sec id="article-30241.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>To prevent toxicity, patients with hepatic impairment should be given a lower dose since the drug's elimination is lower than that of healthy patients. Additionally, tolterodine demonstrated higher concentrations in patients with renal impairment. Therefore, recommendations include a decrease in drug dosage in both patients with hepatic or renal impairment.&#x000a0;</p>
      </sec>
      <sec id="article-30241.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>All clinicians prescribing tolterodine should be familiar with the potential adverse effects. Managing tolterodine therapy should involve the efforts of an interprofessional healthcare team, including clinicians, specialists, mid-level practitioners, nurses, and pharmacists, all coordinating their activities and exercising open communication so that optimal patient outcomes are achieved with minimal adverse effects. [Level 5] Nurses can counsel patients on proper dosing and administration and what to watch for regarding possible adverse events. Pharmacists can reinforce those points and also check the patient's medication profile for potential interactions and contraindications.</p>
        <p>Patients require monitoring for any possible cardiac or central nervous system disturbances, especially those older, as there is a higher probability of drug interactions in this population of patients. Patients should also understand potential common side effects, such as drowsiness or blurred vision, to ensure their safety and to decrease the risk of an accident were they to perform a potentially dangerous task.</p>
      </sec>
      <sec id="article-30241.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30241&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30241">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30241/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30241">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30241.s11">
        <title>References</title>
        <ref id="article-30241.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Staskin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Herschorn</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fialkov</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tu</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schermer</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).</article-title>
            <source>Int Urogynecol J</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>273</fpage>
            <page-range>273-283</page-range>
            <pub-id pub-id-type="pmid">28620791</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gacci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sebastianelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schiavina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brunocilla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Novara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Nunzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oelke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gravas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tolterodine in the Treatment of Male LUTS.</article-title>
            <source>Curr Urol Rep</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>60</fpage>
            <pub-id pub-id-type="pmid">26149965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gacci</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Novara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Nunzio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tubaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schiavina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brunocilla</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Sebastianelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oelke</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gravas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Serni</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.</article-title>
            <source>BMC Urol</source>
            <year>2014</year>
            <month>Oct</month>
            <day>27</day>
            <volume>14</volume>
            <fpage>84</fpage>
            <pub-id pub-id-type="pmid">25348235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Roehrborn</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Chancellor</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Carlsson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bavendam</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.</article-title>
            <source>BJU Int</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>102</volume>
            <issue>9</issue>
            <fpage>1133</fpage>
            <page-range>1133-9</page-range>
            <pub-id pub-id-type="pmid">18510659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sebastianelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Kaplan</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>McVary</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Moncada</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gravas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chapple</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morgia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Serni</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gacci</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms/overactive bladder: Comparison with placebo and tolterodine.</article-title>
            <source>Int J Urol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>3</issue>
            <fpage>196</fpage>
            <page-range>196-205</page-range>
            <pub-id pub-id-type="pmid">29205506</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leone Roberti Maggiore</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Salvatore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alessandri</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Remorgida</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Origoni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Candiani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Venturini</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Ferrero</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and toxicity of antimuscarinic drugs for overactive bladder treatment in females.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2012</year>
            <month>Nov</month>
            <volume>8</volume>
            <issue>11</issue>
            <fpage>1387</fpage>
            <page-range>1387-408</page-range>
            <pub-id pub-id-type="pmid">22871042</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruscin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Morgenstern</surname>
                <given-names>NE</given-names>
              </name>
            </person-group>
            <article-title>Tolterodine use for symptoms of overactive bladder.</article-title>
            <source>Ann Pharmacother</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>33</volume>
            <issue>10</issue>
            <fpage>1073</fpage>
            <page-range>1073-82</page-range>
            <pub-id pub-id-type="pmid">10534221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ellsworth</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Borgstein</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Nijman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>PP</given-names>
              </name>
            </person-group>
            <article-title>Use of tolterodine in children with neurogenic detrusor overactivity: relationship between dose and urodynamic response.</article-title>
            <source>J Urol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>174</volume>
            <issue>4 Pt 2</issue>
            <fpage>1647</fpage>
            <page-range>1647-51; discussion 1651</page-range>
            <pub-id pub-id-type="pmid">16148673</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rajabalaya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Leen</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chellian</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chakravarthi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>David</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder.</article-title>
            <source>Pharmaceutics</source>
            <year>2016</year>
            <month>Aug</month>
            <day>31</day>
            <volume>8</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">27589789</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30241.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hesch</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Agents for treatment of overactive bladder: a therapeutic class review.</article-title>
            <source>Proc (Bayl Univ Med Cent)</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>307</fpage>
            <page-range>307-14</page-range>
            <pub-id pub-id-type="pmid">17637888</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
